World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
153
Citations
97714
World Ranking
1034
National Ranking
590

Overview

Michael Heinrich is affiliated with Oregon Health & Science University in the United States and specializes in medical research with a primary focus on gastrointestinal tumors and related disorders. Their extensive publication record highlights a career dedicated to advancing understanding and treatment in the fields of medicine, particularly within gastroenterology and oncology.

The main fields of study for this researcher encompass Medicine, with detailed work in subfields including Pulmonary and Respiratory Medicine, Gastroenterology, Hematology, Surgery, and Genetics. Their research covers various aspects of gastrointestinal tumor research and treatment, gastric cancer management and outcomes, gastrointestinal disorders and treatments, chronic myeloid leukemia treatments, sarcoma diagnosis and treatment, chronic lymphocytic leukemia research, and platelet disorders and treatments.

Michael Heinrich's frequent coauthors include Suzanne George, Sebastian Bauer, Robin L. Jones, Margaret von Mehren, and César Serrano, reflecting ongoing collaborations within their research network.

Their common publication venues are diverse but centered primarily in clinical oncology and cancer research, featuring notable contributions to:

  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Annals of Oncology
  • Blood
  • Clinical Cancer Research

Notable recent papers authored or coauthored by Michael Heinrich include:

  • Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial, 2020, The Lancet Oncology
  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor, 2023, Journal of Clinical Oncology
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial, 2021, European Journal of Cancer
  • Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study, 2021, Journal of Clinical Oncology

The scope of Michael Heinrich's work reflects a systematic approach to understanding and treating gastrointestinal stromal tumors and related cancer types. Through clinical trials and translational research, they contribute to the evolving standards of care within oncology, particularly focusing on targeted therapies for specific genetic mutations.

Best Publications

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Anette Duensing;Laura McGreevey

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Biology of gastrointestinal stromal tumors.

    Christopher L. Corless;Jonathan A. Fletcher;Michael C. Heinrich

  • Medicinal plants in Mexico: healers' consensus and cultural importance.

    Michael Heinrich;Anita Ankli;Barbara Frei;Claudia Weimann

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

    Thomas O'Hare;Denise K. Walters;Eric P. Stoffregen;Taiping Jia

  • Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

    Michael C. Heinrich;Diana J. Griffith;Brian J. Druker;Cecily L. Wait

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

    Anne Marie O'Farrell;Tinya J. Abrams;Helene A. Yuen;Theresa J. Ngai

  • PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

    Christopher L. Corless;Arin Schroeder;Diana Griffith;Ajia Town

  • Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Hibiscus sabdariffa L. - A phytochemical and pharmacological review

    Inês Da-Costa-Rocha;Bernd Bonnlaender;Hartwig Sievers;Ivo Pischel

  • Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Robert G. Maki;Christopher L. Corless;Cristina R. Antonescu

  • Gastrointestinal stromal tumours: origin and molecular oncology

    Christopher L. Corless;Christine M. Barnett;Michael C. Heinrich

  • Gastrointestinal stromal tumour

    Brian P Rubin;Michael C Heinrich;Michael C Heinrich;Christopher L Corless;Christopher L Corless

  • Clinical management of gastrointestinal stromal tumors : before and after STI-571

    Ronald P. Dematteo;Michael C. Heinrich;Wa'el M. El-Rifai;George Demetri

  • Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies

    Michael C. Heinrich;Charles D. Blanke;Brian J. Druker;Christopher L. Corless

Frequent Co-Authors

Christopher L. Corless
Christopher L. Corless Oregon Health & Science University
Brian J. Druker
Brian J. Druker Oregon Health & Science University
Jonathan A. Fletcher
Jonathan A. Fletcher Brigham and Women's Hospital
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Margaret von Mehren
Margaret von Mehren Fox Chase Cancer Center
Suzanne George
Suzanne George Harvard University
Michael W. Deininger
Michael W. Deininger University of Utah
Otto Sticher
Otto Sticher ETH Zurich
Brian P. Rubin
Brian P. Rubin Cleveland Clinic
Heikki Joensuu
Heikki Joensuu University of Helsinki

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternate or supplementary pathways in healthcare can enhance your career options beyond traditional medical school. Many students are considering accredited online degrees, which offer both flexibility and affordability.

If your interests align with mental health, there are shortest post master's pmhnp online programs available to help you quickly become a Psychiatric Mental Health Nurse Practitioner. This can be a rewarding alternative for those who wish to provide mental healthcare.

Healthcare administration is another growing field. You can start by pursuing the cheapest online healthcare administration degree, and later advance with the cheapest online master degree in healthcare administration. These degrees prepare you for leadership roles in healthcare settings without clinical requirements.

For those seeking the highest nursing credentials, the best dnp programs online provide a pathway to advanced clinical practice and executive positions.

Online degrees make it easier than ever to join and excel in the healthcare industry while aligning your educational investment with your professional goals.

Best Scientists Citing Michael Heinrich

Trending Scientists

Recently Published Articles